Loading company…
UK-based provider of molecular imprinted polymers and synthetic affinity reagents for diagnostics, pharma and cell and gene therapy.
Tozaro Limited, formerly MIP Discovery Limited, provides molecular imprinted polymers for diagnostic, pharmaceutical, biotechnology and research uses, along with synthetic affinity reagents for cell and gene therapy. Founded in 2015 and based in the UK, the company is at the Series A stage. In February 2024 it raised GBP 6.4 million in Series A funding led by Mercia Ventures, with participation from Calculus Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in